BiPAP联合噻托溴铵和信必可在中重度稳定期COPD治疗与护理干预效果分析
Efficacy of BiPAP combined with tiotropium bromide and COPD treatment and nursing intervention in moderate to severe stable phase
梁敏娇 1朱丹 1陈淑娴1
作者信息
- 1. 台州恩泽医疗中心(集团)台州医院 呼吸内科,浙江 台州 317000
- 折叠
摘要
目的 评价中重度稳定期COPD临床治疗中双水平无创正压通气(BiPAP)+噻托溴铵+信必可联合方案应用效果.方法 以210例中重度稳定期COPD患者作为研究对象,分为Ⅰ组、Ⅱ组、Ⅲ组,Ⅰ组采用BiPAP+噻托溴铵治疗方案,Ⅱ组实施噻托溴铵+信必可治疗方案,Ⅲ组启用BiPAP+噻托溴铵+信必可方案.结果 组内比较肺功能各项指标水平发现治疗后3组肺功能各项指标均呈上升趋势,组间比较治疗后肺功能各项指标水平显示Ⅲ组升幅最显著,Ⅰ、Ⅱ组肺功能各项指标升幅差异无统计学意义.组间比较6-MWD指标差异显示Ⅲ组距离最长(P<0.05),Ⅱ组次之,与Ⅰ组差异无统计学意义.结论 BiPAP+噻托溴铵+信必可是中重度稳定期COPD的有效治疗方案,利于患者生活质量提高.
Abstract
Objective To evaluate the level of clinical treatment in severe stable double COPD noninvasive positive pressure ventilation (BiPAP) + tiotropium + Symbicort regimen effect. Methods 210 patients with moderate to severe COPD patients as the research object, divided into group I, group II, group III, 1 BiPAP + group with tiotropium bromide in the treatment scheme, group II Implementation of tiotropium + Symbicort treatment group enabled BiPAP + tiotropium + Symbicort. Results Group comparison indexes of pulmonary function level and lung function indexes were found in the three groups after treatment showed a rising trend comparison between groups after treatment, the levels of the indicators of lung function showed the most significant increases in group I, group II indexes of pulmonary function approximation. In group 6-MWD group with the longest distance difference index (P<0.05), group II and group I but the difference between does not have statistical significance Conclusion BiPAP + tiotropium bromide + Cr is an effective treatment for moderate and severe stable COPD, which is beneficial to improve the quality of life of patients.
关键词
双水平无创正压通气/噻托溴铵/信必可/COPDKey words
bi level noninvasive positive pressure ventilation/tiotropium bromide/symbicort/COPD引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据